Advanced Filters
noise

immune-thrombocytopenic-purpura Clinical Trials

A listing of immune-thrombocytopenic-purpura medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 90 clinical trials
M Mohsin Elalfy, Professor

Management of Children With Persistent ITP, A Novel Approach

The goal of this clinical trial is to learn if mini-pool intravenous immunoglobulin (IVIG) is a safe and effective treatment for children with persistent immune thrombocytopenia (ITP). ITP is a condition that causes low platelet levels and increases the risk of bleeding. The main questions this study aims to answer …

1 - 10 years of age All Phase N/A
Z Zhenyu Yan, Doctor

A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are: To evaluate the safety and tolerability of CID-103 in subjects with …

18 - 65 years of age All Phase 1/2
H Hongjuan Lu

The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP

The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus dexamethasone (DEX) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults. It will also learn about the safety of HCQ plus DEX. The main questions it aims to answer are: Does HCQ plus DEX …

15 - 75 years of age All Phase N/A
H Hongjuan Lu

The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP

The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus prednisone (Pred) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults. It will also learn about the safety of HCQ plus Pred. The main questions it aims to answer are: Does HCQ plus Pred …

15 - 99 years of age All Phase N/A
H Hongjuan Lu

The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus thrombopoietin receptor agonists (TPO-RA) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults. It will also learn about the safety of HCQ plus TPO-RA. The main questions it aims to answer are: Does HCQ …

15 - 99 years of age All Phase N/A
Y Yunfei Chen, MD

A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

The objective of this study was to evaluate the efficacy and safety of Herombopag in the treatment of elderly patients with ITP.

60 years of age All Phase 2
A Alaa Alwan, MD

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and continued for up to 24 weeks. The study aims to acquire experience on use of avatrombopag …

18 years of age All Phase 4

The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids

Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. The diagnosis is typically made by excluding the known causes of thrombocytopenia. IgG autoantibodies sensitize the circulating platelets. It leads to the accelerated removal of these cells by …

1 - 18 years of age All Phase N/A
J Junyuan Qi, MD. PHD

Safety Study of CC312 in Autoimmune Disease Patients

This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune diseases. The trial also assesses pharmacokinetics (PK) and preliminary efficacy. CC312 is a trispecific T cell engager (TriTE) that targets the …

18 years of age All Phase 0

Safety and Efficacy of Fecal Microbiota Transplantation

The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease states. Fecal microbiota transplantation (FMT), defined as infusion of feces from healthy donors …

years of age All Phase N/A

Simplify language using AI